BioHarvest Sciences (NASDAQ:BHST) Raised to Hold at Wall Street Zen

Key Points

• BioHarvest Sciences (NASDAQ:BHST) has been upgraded to a "hold" rating by Wall Street Zen, while Weiss Ratings reiterated a "sell" rating.
• The company reported a quarterly loss of ($0.15) earnings per share, missing the consensus estimate and showing a negative net margin of 39.95%.
• The stock currently has an average price target of $13.67 and a market capitalization of $181.50 million.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a research report issued on Saturday.

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of BioHarvest Sciences in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $13.67.

BioHarvest Sciences Price Performance

NASDAQ:BHST opened at $11.05 on Friday. BioHarvest Sciences has a fifty-two week low of $4.66 and a fifty-two week high of $12.80. The stock has a market capitalization of $181.50 million, a PE ratio of -15.79 and a beta of 0.78. The business's 50-day simple moving average is $9.45 and its 200-day simple moving average is $7.63.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%. The business had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. On average, research analysts expect that BioHarvest Sciences will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC raised its position in BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 7.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 44,391 shares of the company's stock after acquiring an additional 3,120 shares during the period. True North Advisors LLC owned about 0.27% of BioHarvest Sciences worth $275,000 as of its most recent filing with the SEC.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.